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Abstract: Radiotherapy is a cancer treatment that applies high doses of ionizing radiation to induce
cell death, mainly by triggering DNA double-strand breaks. The outcome of radiotherapy greatly
depends on radiosensitivity of cancer cells, which is determined by multiple proteins and cellular
processes. In this review, we summarize current knowledge on the role of microRNAs (miRNAs)
and long non-coding RNAs (lncRNAs), in determining the response to radiation. Non-coding RNAs
modulate ionizing radiation response by targeting key signaling pathways, including DNA damage
repair, apoptosis, glycolysis, cell cycle arrest, and autophagy. Additionally, we indicate miRNAs and
lncRNAs that upon overexpression or inhibition alter cellular radiosensitivity. Current data indicate
the potential of using specific non-coding RNAs as modulators of cellular radiosensitivity to improve
outcome of radiotherapy.
Keywords: non-coding RNA; miRNA; lncRNA; circRNA; radiation response; radiotherapy
1. Introduction
Radiation therapy is a common treatment for many types of cancer, either alone or in combination
with other therapeutic approaches. Different tumor types vary in their sensitivity to radiotherapy [1].
The response to radiation treatment is mediated by cellular processes such as DNA damage repair,
apoptosis, cell cycle redistribution, etc., and some tumors exhibit high level of radioresistance. For an
effective treatment, patients with radioresistant tumors require higher doses of irradiation which
will lead to undesired side effects. Identification of factors leading to radioresistance and markers of
radiosensitivity is crucial for identifying responsive patients and improving the outcome of radiotherapy.
Recently, it has been demonstrated that expression patterns of non-coding RNAs (ncRNAs) after
ionizing radiation (IR) differ between radioresistant and radiosensitive tumors [2–7].
Non-coding RNAs are a diverse group of functional RNA molecules that are not translated into
proteins. Non-coding RNAs are predominant in the genome and can be divided into housekeeping
ncRNAs, such as transfer RNAs (tRNA) and ribosomal RNAs (rRNA), and regulatory ncRNAs,
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which can be divided into small (<200 nt) ncRNAs, including microRNAs (miRNAs), and long (>200 nt)
ncRNAs (lncRNAs) [8]. miRNAs are single-stranded, ~22 nt long ncRNAs that bind to a short core
sequence mainly in the 3′ untranslated region (UTR) of target messenger RNA (mRNA) and lead
to inhibition of translation or mRNA degradation [9,10]. lncRNAs are the largest class of ncRNAs
with currently a total of >90,000 annotated genes [11]. A subset of the lncRNAs are circular RNAs
(circRNAs) that are formed during splicing of linear transcripts (both protein coding and non-coding)
into covalently closed single-stranded RNA molecules [12]. Regulation of gene expression by lncRNAs
is more complex as they can interact with DNA, RNA, or proteins and act as transcriptional modulators,
RNA splicing regulators, microRNA sponges, RNA-binding protein (RBP) sponges, and scaffolds to
form ribonucleoprotein complexes [13–15]. Aberrant miRNA and lncRNA expression signatures have
been reported for most cancer types and some of these ncRNAs were shown to impact on cellular
functions such as cell proliferation and resistance to apoptosis.
Current studies revealed several mechanisms through which ncRNAs contribute to response to
radiotherapy. Here, we summarize the main findings on ncRNAs involved in crucial pathways in
response to radiotherapy in cancer. We focused on miRNAs and lncRNAs that regulate DNA double
strand breaks (DSBs) repair, apoptosis, autophagy, cell cycle progression, glycolysis and Wnt/β-catenin
pathway in response to IR. We also present an overview of ncRNAs that alter radiosensitivity of cancer
cells (Tables 1 and 2) and discuss the utilization of ncRNAs to improve the outcome of radiotherapy.
Table 1. microRNAs (miRNAs) promoting radiosensitivity or radioresistance in cancer cells.
miRNA Target Pathway Cancer Type Reference
miRNA Promoting Radiosensitivity
let-7 Cyclin D1 Cell cycle Uveal melanoma *, breast cancer [16,17]
miR-16 Cyclin D1 Cell cycle Prostate cancer [18]
miR-18a ATM DSB repair Breast cancer, lung cancer * [19,20]
HIF-1α - Lung cancer * [20]
miR-22 SIRT1 Apoptosis Breast cancer [21]
miR-23b ATG12 Autophagy Pancreatic cancer * [22]
miR-24 H2AX DSB repair Leukemia [23]
miR-26a ATM DSB repair Glioma [24]
miR-26b DRAM1 Autophagy Breast cancer [25]
miR-30a TP53INP1 Autophagy Prostate cancer [26]
miR-33a HIF-1α Glycolysis Melanoma * [27]
miR-34a LyGDI Apoptosis NSCLC [28]
RAD51 DSB repair Lung cancer * [29]
miR-99a mTOR Apoptosis NSCLC * [30]
miR-100 ATM - Glioma [31]
miR-101 DNA-PKcs - Glioma * [32]
ATM - Glioma * [32]
STMN1 Autophagy NPC [33]
miR-107 RAD51 DSB repair Ovarian cancer [34]
miR-124 CDK4 Apoptosis Glioma, ESCC [35,36]
STAT3 Apoptosis NSCLC *, breast cancer [37,38]
PIM 1 - Prostate cancer [39]
miR-125a p21 - Cervical cancer [40]
miR-125b c-Jun Apoptosis Breast cancer [41]
miR-133a EGFR Apoptosis ESCC [42]
miR-133b PKM2 Glycolysis NSCLC [43]
miR-136 E2F1 Apoptosis Cervical cancer [44]
Cancers 2020, 12, 1662 3 of 27
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miRNA Target Pathway Cancer Type Reference
miR-138 H2AX DSB repair Osteosarcoma [45]
miR-144 PIM 1 - Prostate cancer [39]
miR-150 AKT Apoptosis NK/T cell lymphoma * [46]
miR-153 Bcl-2 Apoptosis Glioma * [47]
miR-155 RAD51 DSB repair Triple negative breast cancer * [48]
miR-182 BRCA1 DSB repair Breast cancer [49]
miR-185 Wnt2B Wnt/β-catenin NPC [50]
miR-193a Mcl-1 Apoptosis GBM, cervical cancer [51]
miR-199a Beclin-1,DRAM1 Autophagy Breast cancer [52]
miR-200c UBQLN1 Autophagy Breast cancer [53]
miR-203a ATM Apoptosis, cell cycle, migration Ovarian cancer [54]
miR-205 TP53INP1 Autophagy Prostate cancer [26]
miR-214 ATG12 Autophagy CRC * [55]
miR-216a Beclin-1 Autophagy Pancreatic cancer * [56]
miR-222 RAD51 DSB repair Ovarian cancer [34]
miR-223 ATM - Glioma * [57]
miR-301a Wnt Wnt/β-catenin, migration ESCC [58]
miR-302a AKT,RAD52 - Breast cancer * [59]
miR-320a STAT3 Apoptosis, metastasis NSCLC * [60]
β-catenin Wnt/β-catenin Cervical cancer [61]
miR-324-3p Wnt2B Wnt/ β-catenin NPC [62]
miR-421 ATM DSB repair SCC [63]
miR-448 HIF-1α Glycolysis Glioma [64]
miR-449a LDHA Glycolysis, apoptosis Lung cancer [65]
miR-449a c-MYC Cell cycle Prostate cancer * [66]
miR-450a DUSP10 Autophagy ESCC * [67]
miR-634 STAT3 Apoptosis Breast cancer [68]
miR-770 PBK Apoptosis CRC * [69]
miR-875 EGFR DSB repair Prostate cancer * [70]
miR-1275 Wnt1 Wnt/β-catenin, EMT, ESCC * [71]
miRNA Promoting Radioresistance
miR-17 P21 Apoptosis OSCC * [72]
PTEN Apoptosis, cell cycle NPC [73]
miR-20a PTEN Apoptosis HCC [74]
miR-21 PTEN Migration Leukemia, NSCLC [75,76]
miR-29a PTEN - CRC [77]
miR-96 PTEN - HNSCC [78]
miR-106b PTEN,p21 Apoptosis, cell cycle CRC [79]
miR-135b GSK3β - GBM [80]
miR-150 GSK3β - NPC [81]
miR-155 UBQLN1 - NPC [82]
Cancers 2020, 12, 1662 4 of 27
Table 1. Cont.
miRNA Target Pathway Cancer Type Reference
miR-205 PTEN Apoptosis NPC [83]
miR-208a p21 Lung cancer [84]
miR-210 AIFM3 Apoptosis Hepatoma [85]
miR-212 BRCA1 Apoptosis Glioma [86]
miR-214 PTEN - Ovarian cancer * [87]
miR-221/miR-222 PTEN Apoptosis, migration CRC, gastric cancer, GBM [88–91]
miR-300 p53,Apaf-1 Apoptosis, cell cycle, senescence Lung cancer [92]
miR-301a TCEAL7 Wnt/β-catenin, apoptosis GBM * [93]
miR-375 p53 Apoptosis, cell cycle Gastric cancer [94]
miR-498 PTEN Apoptosis, migration Prostate cancer [95]
miR-622 Rb Apoptosis CRC [96]
miR-1246 mTOR Autophagy NSCLC [97]
* Effect on radiosensitivity/radioresistance observed in vivo; HNSCC—head and neck squamous cell carcinoma;
HCC—hepatocellular carcinoma; NPC—nasopharyngeal carcinoma; CRC—colorectal cancer; NSCLC—non-small
cell lung cancer; OSCC—oral squamous cell carcinoma; ESCC—esophageal squamous cell carcinoma;
GBM—glioblastoma; NK/T-cell lymphoma—natural killer/T-cell lymphoma; DSB—DNA double strand break.
Table 2. Long non-coding RNAs (lncRNAs) promoting radiosensitivity or radioresistance in cancer cells.
lncRNA Target Pathway Cancer Type Reference
lncRNA Promoting Radiosensitivity
circATRNL1 miR-23a/PTEN Apoptosis, cell cycle OSCC [98]
lincRNA-p21 β-catenin Wnt/β-catenin Gastric cancer [99]
- Wnt/β-catenin CRC [100]
MEG3 miR-182 DSB repair Thyroid cancer [101]
NEAT1 miR-101/EMP2 Apoptosis, EMT NPC * [102]
OIP5-AS1 miR-369/DYRK1A Apoptosis CRC [103]
lncRNA Promoting Radioresistance
BOKAS WISP1 Wnt/β-catenin ESCC [104]
BLACAT1 PSEN1 Apoptosis, cell cycle DSB repair HNSCC [105]
CCAT1 miR-148 Apoptosis Breast cancer [106]
circPITX1 miR-329-3p/NEK2 Glycolysis Glioma * [107]
circPTK2 miR-369/ZEB1 Apoptosis Gastric cancer * [108]
CRNDE - Apoptosis Lung adenocarcinoma [109]
CYTOR - Apoptosis NSCLC [110]
DNM3OS - DSB repair ESCC * [111]
FAM83H-AS1 HuR DSB repair Ovarian cancer [112]
HOTAIR p21 Apoptosis, cell cycle Cervical cancer * [113]
WIF-1 Wnt/β-catenin Pancreatic cancer [114]
miR-218 Apoptosis, cell cycle, DSB repair Breast cancer [115]
LC3-II, ATG7 Autophagy, apoptosis Pancreatic cancer [116]
HULC LC3B-II, Beclin-1 Apoptosis, autophagy Prostate cancer [117]
LINC00963 miR-324-3p/ACK1 DSB repair Breast cancer [118]
LINC02582 miR-200c/USP7/CHK1 DSB repair Breast cancer * [119]
lincRNA-p21 HIF-1α Autophagy Hepatoma, Glioma [120]
lincRNA-ROR P53, miR-145 Apoptosis CRC* [121]
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Table 2. Cont.
lncRNA Target Pathway Cancer Type Reference
LINP1 Ku80, DNA-PKcs Apoptosis, DSB repair Cervical cancer [122]
MALAT1 Cks1 Apoptosis ESCC * [123]
miR-1/SLUG Apoptosis NP C* [124]
miR-145 Apoptosis, cell cycle Cervical cancer [125]
NEAT1 miR-204/ZEB1 Apoptosis NPC [126]
miR-193b/Cyclin D1 Apoptosis, cell cycle Cervical cancer * [127]
PCAT6 miR-185/TPD52 Apoptosis, cell cycle Breast cancer [128]
POU6F2-AS2 YBX1 DSB repair ESCC [129]
PVT1 miR-195 Apoptosis, DSB repair NSCLC * [130]
ATM, p53, CHK2 Apoptosis, DSB repair NPC * [131]
HIF-1α DSB repair NPC [132]
SBF2-AS1 miR-302a/MBNL3 Apoptosis NSCLC * [133]
TP73-AS1 PTEN, AKT Apoptosis HCC * [134]
TUG1 HMGB1 Apoptosis Bladder cancer * [135]
UCA1 AKT, FAK, FGR,AMPKα1 Cell cycle Gastric cancer [136]
UCA1 HK2 Glycolysis Cervical cancer [137]
* Effect on radiosensitivity/radioresistance observed in vivo; HNSCC—head and neck squamous cell carcinoma;
HCC—hepatocellular carcinoma; NPC—nasopharyngeal carcinoma; CRC—colorectal cancer; NSCLC—non-small
cell lung cancer; OSCC—oral squamous cell carcinoma; ESCC—esophageal squamous cell carcinoma; lincRNA—long
intergenic noncoding RNA.
2. ncRNAs Involved in DSB Repair
DNA double strand breaks (DSBs) are the most prevalent and deleterious type of damage induced
by IR. If not repaired correctly, it can lead to cell death or chromosomal aberrations and genomic
instability. Cells use two major mechanisms to repair DSBs, the non-homologous end joining (NHEJ)
and homologous recombination (HR) pathways. The NHEJ pathway ligates broken DNA ends directly,
whereas HR employs a homologous DNA template from the sister chromatid [138]. Both pathways
require several proteins, which cooperate to detect (ATM, ATR, CHK1, CHK2), signal (γH2AX) and
repair DSBs (BRCA1, BRCA2, Ku80, DNA-PKcs) [139,140]. Recently, the role of ncRNAs in DSB
repair has been recognized [141]. Here, we summarize ncRNAs involved in DSB repair following IR
(Figure 1).
2.1. miRNAs
Two miRNAs, miR-24, and miR-138 were shown to directly regulate H2AX upon IR.
Phosphorylated H2AX (γH2AX) foci are early markers of DSBs, since H2AX recruits DNA repair
proteins to DSB damage sites [142]. Overexpression of miR-24 decreased H2AX levels resulting in a
diminished capacity to repair DSBs upon γ-irradiation in differentiated leukemic cells. DSB repair
was restored by overexpressing a miR-24-insensitive H2AX gene [23]. A similar effect was shown
in osteosarcoma cells where miR-138 mimics reduced formation of γH2AX foci, increased genomic
instability and enhanced cellular sensitivity to IR [45].
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carcinoma (SCC) [19,24,63]. BRCA1, another important protein in HR, was suppressed by miR-182 in 
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Figure 1. Non-coding RNAs (ncRNAs) regulating onizing radiation (IR)-induce DSB repair. ncRNAs
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Several miRNAs were reported to sensitize cells to radiotherapy by inhibiting expression of
proteins involved in the HR pathway. A key player in HR, ataxia telangiectasia mutated (ATM),
was downregulated by miR-18a in breast cancer, miR-26a in glioma and miR-421 in squamous cell
carcinoma (SCC) [19,24,63]. BRCA1, another important protein in HR, was suppressed by miR-182
in breast cancer cells [49]. The HR pathway was also impaired by miR-875 which directly targeted
epidermal growth factor receptor (EGFR) and inhibited the EGFR-ZEB1-CHK1 axis. Overexpression
of miR-875 enhanced radiosensitivity in prostate cancer cell lines in vitro and in xenograft models
through targeting EGFR [70].
Several studies sho d a miRNA-mediated regula ion of RAD51 expression and the subsequent
formation of RAD51 foci in response to IR, an important step in HR. RAD51 was identified as a direct
target of miR-34a, miR-107, miR-155 nd miR-222 upon IR. Overexpression of miR-34a in lung ancer
cells reduced formation of radiation-induced RAD51 foci. This phenotype could be rescued by RAD51
reintroduction. In mouse models administration of MRX34, a liposomal nanoparticle loaded with
miR-34a imics, sensitized lung tumors to radiation by repressing RAD51 [29]. A similar effect was
observed for miR-107 and miR-222 mimics in ovarian cancer cells and for overexpression of miR-155
in breast cancer cells [34,48]. Additionally, high miR-155 levels were associated with lower RAD51
expression and better overall survival of patients in a large series of triple-negative breast cancers [48].
2.2. lncRNAs
PVT1 was upregulated in patients with nasopharyngeal carcinoma (NPC). PVT1 knockdown
enhanced radiosensitivity of NPC cells in vitro and in vivo, which could be attributed to increased
apoptosis rate after IR. Decreased phosphorylation of key mediators of DNA damage response, i.e.,
ATM, p53 and CHK2, was observed in irradiated NPC cells with PVT1 knockdown [131]. This suggests
impaired DSB repair upon PVT1 knockdow , how ver, the level and re ir dynamics of IR-induced
DSBs was not studied. Wang et al. further showed that PVT1 increased stability of HIF-1α in NPC
cells [132]. PVT1 acted as a scaffold for histone acetyltransferase KAT2A, which promoted H3K9
acetylation at the promoter of NF90, a known regulator of HIF-1α expression and stability.
Two lncRNAs, POU6F2-AS2 and DNM3OS, were involved in DSB repair in esophageal squamous
cell carcinoma (ESCC). Downregulation of POU6F2-AS2 and DNM3OS promoted ra iosensitivity of
ESCC cells and impaired DSB r pair [111,129]. Analysis of proteins interacting with POU6F2-AS2
revealed among others YBX1, a RNA and DNA binding protein involved in DNA damage response.
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Ectopic expression of YBX1 partially rescued sensitivity to IR caused by POU6F2-AS2 knockdown,
indicating a functional link between POU6F2-AS2 and YBX1 in IR response. Furthermore, it was
demonstrated that POU6F2-AS2 is required for YBX1 binding to chromatin, especially to the sites
of DNA breaks [129]. DNM3OS knockdown increased the extent of IR-induced DNA damage and
impaired DSB repair, as demonstrated by the higher number of γH2AX foci after IR, higher tail
moment in comet assay and reduced induction of DNA repair proteins. Interestingly, expression of
DNM3OS and radioresistance were promoted by cancer-associated fibroblasts, which are an important
component of the tumor environment in ESCC [111].
LINP1 transcripts are localized predominantly in the cytoplasm of Hela S3 cells, but are upregulated
and rapidly translocated to the nucleus after IR. Knockdown of LINP1 enhanced radiosensitivity
of cervical cancer cells by increasing apoptosis and impairing DSB repair after IR. RNA pulldown
revealed association of LINP1 with Ku80 and DNA-PKcs, which suggests that LINP1 is involved in the
NHEJ pathway. However, the effect of LINP1 knockdown on Ku80 and DNA-PKcs function was not
investigated [122].
Several lncRNAs involved in repair of IR-induced DNA damage interacted with miRNAs.
LINC02582 was identified as a direct target of miR-200c in breast cancer, and it promoted radioresistance
of breast cancer cells in vitro and in vivo. Upon LINC02582 silencing, the number of irradiation-induced
γH2AX foci increased and they persisted longer, which indicated that LINC02582 is involved in
DSB repair. Further analysis revealed an interaction of LINC02582 with USP7, a deubiquitinating
enzyme stabilizing among others the CHK1 kinase, a crucial player in DNA damage repair.
The authors proved that LINC02582 stabilizes CHK1 via USP7 and demonstrated the significance of
the miR-200c/LINC02582/USP7/CHK1 axis in radioresistance of breast cancer cells [119].
Other lncRNA–miRNA interactions reported in DNA damage repair include LINC00963 with
miR-324-3p and HOTAIR with miR-218 in breast cancer, and MEG3 with miR-182 in thyroid
cancer [101,115,118]. miR-218 and miR-182 counteracted the effect of their respective target lncRNAs
on DNA damage repair.
3. ncRNAs Regulating IR-Induced Apoptosis
After exposure to IR, cell death regulatory pathways are activated to eliminate cells with extensive
burden of DNA damage [143]. In case repair of IR-induced DNA damage fails, the p53-Induced
Death Domain Protein 1 (PIDD) protein is activated in a p53-dependent manner and together with
Death Adaptor Molecule RAIDD and caspase-2 this serves as an activation platform for further
factors [144,145]. Consequently, cytochrome c is released from damaged mitochondria and activation
of caspase-9 triggers a cascade of effector caspases [146]. Several recent studies showed that ncRNAs
can modulate programmed cell death after IR [147,148]. Apoptosis is an acclaimed indicator of cellular
radiosensitivity and a prognostic factor of radiotherapy treatment outcome [149,150]. Apart from
apoptosis, cell death after IR can also occur via necrosis and mitotic catastrophe. However, the evidence
for the role of ncRNA in these processes in response to IR in cancer cells is limited. Below we present
an overview of the ncRNAs involved in modulation of apoptosis after IR (Figure 2).
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3.1. miRNAs
Three miRNAs were shown to modulate IR-induced apoptosis by targeting the TP53 gene or p53
associated proteins. p53 is a crucial tumor suppressor activated in response to IR to induce either cell
cycle arrest or apoptosis [151]. miR-375 directly targeted p53. Overexpression of miR-375 reduced
p53 expression, enhanced radioresistance, and abrogated p53-mediated apoptosis in IR-treated gastric
cancer cells [94]. Apoptotic protease activating factor-1 (Apaf-1), the structural core of the apoptosome,
was shown to be directly regulated by miR-300 in lung cancer cells. Ectopic expression of miR-300
caused radioresistance mediated at least in part by a reduction of Apaf-1-induced apoptosis [92].
Wu et al. showed that p21 protein, a target of p53, was downregulated by miR-17 in oral squamous cell
carcinoma (OSCC) cells. Suppression of miR-17 in xenograft tumors resulted in increased p21 expression,
increased apoptosis rate and enhanced radiosensitivity [72]. miR-210 increased radioresistance of
hypoxic hepatoma cells by targeting apoptosis-inducing factor mitochondria-associated 3 (AIFM3) [85].
Downregulation of miR-210 promoted and AIFM3 inhibition attenuated IR-induced apoptosis in
hypoxic hepatoma cells. miR-622 was shown to prevent apoptosis by inhibiting the retinoblastoma
(Rb) tumor suppressor gene in colorectal cancer cells [96]. The Rb protein can either inhibit or
promote apoptosis [152]. The pro-apoptotic role of Rb is associated with Rb-phosphorylation that
induces formation of the pRb-E2F1-P/CAF complex. Increased miR-622 levels induced radioresistance,
which could be reversed by restoration of Rb. miR-622-mediated Rb inhibition prevented the formation
of pRb-E2F1-P/CAF complex [96]. Another miRNA acting on the same pathway, but via targeting E2F1
is miR-136. Similarly to Rb, E2F1 can also induce or inhibit apoptosis depending on the proteins it is
associated with [153]. The anti-apoptotic role of E2F1 exerted through the NF-κB signaling pathway was
inhibited by miR-136. Overexpression of miR-136 increased radiosensitivity by promoting apoptosis,
and inhibition of proliferation in cervical cancer cells [44].
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Two miRNAs were shown to affect IR-induced apoptosis by targeting two main anti-apoptotic
proteins. Bcl-2 was directly targeted by miR-153 in glioma cells. Levels of miR-153 were lower in
radioresistant glioma clinical specimens and glioma cell lines exposed to IR. Overexpression of miR-153
promoted radiosensitivity and apoptosis in glioma cells. This effect was modulated by Bcl-2 inhibition,
since restoration of Bcl-2 expression reversed the miR-153-induced phenotype. Additionally, miR-153
enhanced the response to IR in xenograft mice [47]. Another pro-apoptotic miRNA, miR-193a, targeted
Mcl-1. Overexpression of miR-193a resulted in increased apoptosis and DNA damage in glioblastoma
(GBM) and cervical cancer cells. This effect could be blocked by antioxidant treatment, indicating the
crucial role of ROS. Importantly, ectopic expression of Mcl-1 suppressed the pro-apoptotic action of
miR-193a, suggesting that Mcl-1 depletion is critical for miR-193a-induced apoptosis [51].
The radiation-inducible miR-770 boosted apoptosis via direct targeting of PDZ-binding kinase
(PBK), which sensitized colorectal cancer (CRC) cells to radiation both in vitro and in vivo [69].
Similarly, radiosensitivity and apoptosis were induced by miR-22-mediated inhibition of SIRT1 in
breast cancer cells, by miR-34a-mediated inhibition of LyGDI in non-small cell lung cancer (NSCLC)
cells and by miR-124-mediated inhibition of CDK4 in ESCC and glioma cells [21,28,35,36]. Moreover,
restoration of SIRT and CDK4 reversed the phenotypes [21,35].
Several miRNAs exert their effects on IR response via targeting components of crucial survival
pathways, i.e., extracellular signal-regulated kinase (ERK), Janus kinase/signal transducer and activator
of transcription (JAK/STAT) and phosphoinositide 3-kinase (PI3K)/AKT. These pathways are initiated
in response to IR-dependent activation of EGFR [154]. The ERK pathway was abrogated by the
miR-133a-dependent inhibition of EGFR. This led to apoptosis and enhanced radiosensitivity of
esophageal cancer cells [42]. Another main player of the ERK pathway, c-Jun is targeted by miR-125b.
Forced expression of miR-125b in breast cancer cells resulted in radiosensitivity, enhanced apoptotic
activity and senescence upon IR. Restored c-Jun abrogated miR-125b-mediated radiosensitization [41].
STAT3, one of the main players in the JAK/STAT pathway, is a direct target of miR-124, miR-320a and
miR-634 [37,60,68]. Overexpression of miR-124 reduced the activity of STAT3 signaling pathway and
enhanced apoptosis upon irradiation in NSCLC and in HER2-positive breast cancer [37,38]. In line with
these findings, low miR-124 and high STAT3 levels were associated with a poor response to radiotherapy
in HER2-positive breast cancer patients [38]. Ectopic expression of miR-320a enhanced IR-induced
apoptosis and radiosensitivity of NSCLC cells both in vitro and in vivo [60]. Overexpression of miR-634
promoted apoptosis in irradiated breast cancer cells [68].
High activity of the PI3K/AKT pathway has been associated with resistance to IR-induced
apoptosis in many cancer types [155]. AKT was reported to be directly targeted by miR-150 in
natural killer (NK)/T-cell lymphoma cells. Overexpression of miR-150 promoted IR-induced apoptosis
by suppressing PI3K/AKT signaling and sensitized NK/T-cell lymphoma cells to radiotherapy in
a xenograft mouse model [46]. Furthermore, miR-203a-mediated ATM downregulation induced
apoptosis and cell cycle arrest in G1 phase in ovarian cancer cells by inhibiting the AKT/GSK3β/Snail
signaling pathway [54]. Another miRNA acting through the PI3K/AKT pathway in NSCLC is miR-99a.
Ectopic miR-99a expression radiosensitized NSCLC cells in vitro and in vivo by reducing levels of
mTOR, one of the downstream targets of AKT kinase [30].
Several miRNAs induce pro-survival signals in response to IR by targeting phosphatase and tensin
homolog (PTEN), a primary inhibitor of the PI3K/AKT pathway. The currently known PTEN-targeting
miRNAs include miR-17, miR-20a, miR-106b, miR-205, miR-221, miR-222, and miR-498. Overexpression
of these miRNAs resulted in activation of the PI3K/AKT pathway, inhibited apoptosis and enhanced
radioresistance [73,74,79,83,88,91,95,156]. Another miRNA that attenuated IR-induced apoptosis was
miR-212 that directly targeted BRCA1 in glioma cells. Ectopically expressed miR-212 promoted
radioresistance which could be phenocopied by BRCA1 knockdown [86].
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3.2. lncRNAs
Several lncRNAs promoted radioresistance by inhibiting IR-induced apoptosis. Knockdown
of lncRNA bladder cancer associated transcript 1 (BLACAT1) accelerated apoptosis of head and
neck squamous cell carcinoma cells (HNSCC) by positively regulating expression of presenilin
1 protein (PSEN1). Levels of BLACAT1 and PSEN1 were also positively correlated in HNSCC
patients. Overexpression of PSEN1 rescued the enhanced radiosensitivity observed upon BLACAT1
knockdown [105].
Radiation significantly elevated the expression of lncRNA TUG1 in bladder cancer cells. IR-induced
apoptosis was noticeably enhanced upon TUG1 silencing and this was due to a downregulation of the
anti-apoptotic HMGB1 protein. Restoration of HMGB1 expression reversed the pro-apoptotic effect of
TUG1 knockdown [135].
Knockdown of lncRNA TP73-AS1 promoted apoptosis and thereby enhanced radiosensitivity of
hepatocellular carcinoma (HCC) cells. This was mediated by upregulated PTEN levels and decreased
AKT phosphorylation in HCC cells upon TP73-AS1 silencing. Moreover, knockdown of TP73-AS1
reduced tumor growth in vivo after IR [134].
LncRNA MALAT1 was downregulated after IR in ESCC cells. Overexpression of MALAT1
enhanced the radioresistance of ESCC cells. It was shown that MALAT1 prevented the downregulation
of cyclin-dependent kinase subunit (Cks1) after IR, which resulted in a decrease in irradiation-induced
apoptosis [123]. MALAT1 and several other lncRNAs also affected IR-induced apoptosis by interacting
with miRNAs. In NPC, knockdown of MALAT1 promoted apoptosis and sensitized NPC cells to
radiation both in vitro and in vivo. MALAT1 sequestered miR-1 and this resulted in increased levels
of the anti-apoptotic SLUG protein [124]. In high risk HPV-positive cervical cancer knockdown of
MALAT1 also enhanced IR-induced apoptosis. MALAT1 directly interacted with miR-145 and the
combined knockdown of MALAT1 and overexpression of miR-145 had a stronger effect on apoptosis
than miR-145 overexpression alone [125]. However, target genes of miR-145 relevant for the effect on
apoptosis were not determined.
Contradictory effects of NEAT1 on IR-induced apoptosis were reported [102,126,127]. Wang et al.
showed that NEAT1 is downregulated, while Lu et al. observed significantly upregulated levels of
NEAT1 in NPC tissues. Wang et al. observed that knockdown of NEAT1 combined with radiation
treatment significantly decreased apoptosis in NPC cells. NEAT1 enhanced the expression of the
pro-apoptotic epithelial membrane protein 2 (EMP2) by sponging miR-101 [102]. On the contrary,
in the study of Lu et al. NEAT1 downregulation reinforced radiosensitivity by enhancing apoptosis of
NPC cells. In this case cellular radioresistance was regulated by the NEAT1/miR-204/ZEB1 axis [126].
The opposite effects of NEAT1 on radiosensitivity and IR-induced apoptosis in NPC cells are difficult
to reconcile, possibly cell line-specific effects may be involved. In cervical cancer NEAT1 was highly
expressed in radioresistant patients. Here, silencing of NEAT1 induced apoptosis in radioresistant
cervical cancer cells. NEAT1 reduced miR-193b levels and enhanced expression of Cyclin D1, suggesting
that NEAT1 can act as a competing endogenous RNA to sequester miR-193b [127].
Expression of long intergenic non-coding RNA-ROR (lincRNA-ROR) was elevated in CRC
cell lines and tissue samples and further induced by IR. Knockdown of lincRNA-ROR enhanced
radiosensitivity of CRC cells by increasing apoptosis after IR and it increased expression of p53 and
miR-145, and affected the levels of p53/miR-145 targets: p21 and MYC [121].
In contrast to lincRNA-ROR, OIP5-AS1 was downregulated in CRC cell lines. OIP-AS1 dependent
downregulation of miR-369 was shown to enhance radiosensitivity and IR-induced apoptosis.
Downregulation of miR-369 led to increased levels of DYRK1A [103].
A miRNA-dependent mechanism was also described for lncRNA SBF2-AS1, which affected
radiosensitivity of NSCLC through modulating miR-302a and its target MBNL3. Both silencing of
SBF2-AS1 and overexpression of miR-302a decreased levels of MBNL3 and promoted apoptosis
of NSCLC cells in vitro and in vivo. Furthermore, miR-302a binds to both SBF2-AS1 and MBNL3
indicating that the observed effect of SBF2-AS1 might be caused by sequestering miR-302a. In line
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with the proposed mechanism, levels of SBF2-AS1 and MBNL3 were elevated, while miR-302a was
downregulated in NSCLC tissues from radioresistant patients [133]. However, MBNL3 has not been
reported previously to be involved in apoptosis, nor did the current study investigate how MBNL3
affects apoptosis.
PVT1 was another lncRNA promoting radioresistance of NSCLC cells. High levels of PVT1
were negatively correlated with miR-195 expression, and IR further increased PVT1 and reduced
miR-195 levels. Direct interaction between PVT1 and miR-195 was demonstrated, and the effect of
PVT1 inhibition on radiosensitivity and apoptosis was reversed by inhibition of miR-195 in vitro and
in vivo [130]. The targets of miR-195 responsible for the effects on apoptosis remain to be identified.
CCAT1 was upregulated, while miR-148 was downregulated in radioresistant compared
to radiosensitive breast cancer tissues. IR further increased CCAT and reduced miR-148 levels.
Downregulation of CCAT1 enhanced caspase3 activity and induced apoptosis of breast cancer cells
after IR. Direct interaction between miR-148 and CCAT1 was demonstrated, and overexpression of
miR-148 copied the effect of CCAT1 knockdown on radiosensitivity and apoptosis of breast cancer
cells [106]. However, target genes of miR-148 relevant for apoptosis remain to be determined.
PCAT6 is an oncogenic lncRNA in various cancer types, among others in triple negative breast
cancer (TNBC). Knockdown of PCAT6 enhanced radiosensitivity of TNBC cells via induction of
apoptosis and G0/G1 cell cycle arrest. Further study revealed that PCAT6 interacted with miR-185 to
promote expression of tumor protein D52 (TPD52) [128], an inhibitor of apoptosis overexpressed in
several tumors [157].
Two circular RNAs have also been shown to modulate cancer cell radiosensitivity by sequestering
miRNAs. circPTK2 was upregulated in gastric cancer tissues. IR further induced expression of
circPTK2 in gastric cancer cell lines and its knockdown enhanced radiosensitivity by inducing apoptosis.
Moreover, knockdown of circPTK2 reduced tumor growth in vivo. The effect on radiosensitivity and
apoptosis was reversed by inhibition of miR-369 which directly interacts with circPTK2. ZEB1 was
identified as the relevant target of miR-369, and its ectopic expression restored radioresistance and
blocked apoptosis upon miR-369 overexpression [108].
circATRNL1 was downregulated in OSCC tissues. IR further reduced expression of circATRNL1
in OSCC cells, while its ectopic overexpression caused radiosensitization of OSCC cells by inducing
apoptosis and promoting cell cycle arrest at G2 phase after IR. This effect was dependent on a direct
interaction between circATRNL1 and miR-23a as shown by phenotype rescue experiments using
miR-23a mimics. This was mediated by the miR-23a target gene PTEN which inactivates the AKT
signaling pathway [98].
4. ncRNAs Involved in IR-Related Autophagy
In normal conditions autophagy is a well-controlled survival mechanism helping to recycle
damaged proteins and cellular organelles. Induction of autophagy leads to formation of
double-membrane vesicles called autophagosomes. This multistep process is controlled by a number
of proteins, i.a. Beclin-1, LC3B-II, mTOR, and autophagy-related proteins (ATG). After fusion of
the autophagosome with endosome and lysosome, the autolysosome is formed [158]. Then the
autolysosome containing cytoplasm-derived contents is degraded together with its inner membrane
by lysosomal hydrolases [158,159]. Autophagy induced by IR plays a crucial role in determining cell
fate: whether cells survive or die and it also affects radiosensitivity [160]. On one hand, autophagy
induced by radiation has a cytoprotective function allowing the cell to eliminate toxic species [161,162].
On the other hand, autophagy can enhance the anticancer effects of some drugs and serve as additional
cell death pathway [162–164]. Below we present an overview of the ncRNAs currently known to be
involved in regulation of IR-induced autophagy (Figure 3).
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T o iR s directly regulate Beclin-1, a central regulator of autophagy that controls
autophagoso e nucleation and aturation [165]. Forced expression of iR-216a in radioresistant
pancreatic cancer cells enhanced radiosensitivity by inhibiting autophagy in response to irradiation.
These effects could be abrogated by overexpression of Beclin-1. Furthermore, miR-216a overexpression
sensitized xenograft tumor to irradiation treatment by inhibiting IR-induced autophagy via targeting
Beclin-1 [56]. Yi et al. showed that miR-199a mimic suppressed IR-induced autophagy in MCF7
breast cancer cells by targeting Beclin-1 and DNA damage-regulated autophagy modulator protein 1
(DRAM1) [52]. DRAM1 is also targeted by miR-26b in breast cancer cells and both overexpression of
miR-26b and inhibition of DRAM1 reduced IR-induced autophagy [25].
i -23b inhibited IR-induced autophagy by targeting ATG12, an ubiquitin-like protein involved
in autophagy vesicles formation. Overexpression of miR-23b inhibited autophagy and sensitized
pancreatic cancer cells to radiation. This effect was also confirmed in a xenograft model upon IR. In line
with this, reduced levels of miR-23b resulted in increased levels of ATG12 and increased autophagy were
observed in radioresistant compared to radiosensitive pancreatic cancer cells. Additionally, miR-23b
expression inversely correlated with autophagy activity in human pancreatic cancer tissues [22].
Similarly, Hu et al. showed that iR-214 promoted radiosensitivity by targeting ATG12 and inhibiting
IR-induced autophagy in CRC both in vitro and in vivo [55].
Several other miRNAs have been shown to inhibit IR-induced autophagy by targeting autophagy
activators. MiR-200c targeted Ubiquilin-1 (UBQLN1), a promoter of autophagosome formation [166].
Ectopic expression of miR-200c sensitized breast cancer cells to irradiation via inhibition of autophagy.
Inverse correlation between the levels of miR-200c, UBQLN1 and autophagy activity was observed in
Cancers 2020, 12, 1662 13 of 27
human breast cancer tissues [53]. Another autophagy activator, Stathmin 1 (STMN1) was identified as
miR-101 target in NPC cells. Ectopic expression of miR-101 suppressed radiation-induced autophagy
of NPC cells. This effect was reversed by STMN1 restoration [33]. A similar effect was shown for
inhibition of Tumor protein 53-induced nuclear protein 1 (TP53INP1) by miR-30a and miR-205 in
prostate cancer cells [26]. MiR-450a targeted DUSP10 and this impaired IR-induced autophagy by
affecting the ERK pathway and regulating ROS elimination. Additionally, tumor xenograft experiments
verified that miR-450a overexpression could increase sensitivity to radiotherapy in radioresistant ESCC
cells in vivo [67].
One miRNA that promoted autophagy in NSCLC cells was miR-1246. Ectopic expression of
miR-1246 downregulated mTOR and decreased radiosensitivity of lung cancer cells both in vitro and
in vivo. Overexpression of mTOR reversed the effect [97].
4.2. lncRNAs
lincRNA-p21 was upregulated after IR and hypoxia treatment in hepatoma and glioma cells lines.
The number of autophagic vesicles upon lincRNA-p21 knockdown was significantly decreased in
hypoxic tumor cells. This effect was mediated by downregulation of HIF-1α and activation of the
AKT/mTOR/p70S6K pathway. Moreover, overexpression of HIF-1α abolished the radiosensitizing
effect of lincRNA-p21 knockdown [120].
HULC regulates sensitivity of prostate cancer cells to IR by modulating microtubule-associated
protein 1 light chain 3B II (LC3B-II), which plays an essential role in the formation of autophagosome.
Overexpression of HULC decreased, and its knockdown increased, LC3B-II expression after IR.
Moreover, HULC can bind to Beclin-1 and increase its phosphorylation at threonine 119 [117].
This leads to dissociation of Beclin-1 from the complex with Bcl-2 protein and in turn results in
activation of autophagy [165], explaining the mode of action of HULC in promoting autophagy [117].
Another lncRNA linked to autophagy is HOTAIR. HOTAIR promoted radiosensitivity of pancreatic
cancer cells by increasing the levels of LC3-II. This indicated that HOTAIR can promote autophagosome
formation. Moreover, HOTAIR enhanced expression of ATG7, a key protein involved in autophagosome
formation that is responsible for vesicle progression [116]. In line with this, Guo et al. demonstrated
that HOTAIR knockdown inhibited autophagy through suppression of the Wnt signaling pathway in
radioresistant human cervical cancer HeLa cells [167].
5. ncRNAs Regulating Cell Cycle in Response to IR
In normal cells IR delays progression through the G1, S, and G2 phases of the cell cycle to allow
for DNA repair and to prevent accumulation of harmful genomic lesions. The central regulator of cell
cycle progression is p53, whose phosphorylation by ATM induces expression and phosphorylation
of the cyclin-dependent kinase inhibitor p21. This leads to inhibition of CDK4/6-cyclin D and
CDK1-cyclin B, causing cell cycle arrest in G1 and G2, respectively [168]. In addition, activation of
signal transducers CHK1 and CHK2 by ATM and ATR promotes degradation of CDC25, leading
to inhibition of CDK2-cyclin E and CDK1-cyclin B, which promotes cell cycle arrest in G1 and G2,
respectively [169]. Effective induction of cell cycle arrest promotes radiosensitivity which means that
the ability to progress through cell cycle after IR contributes to tumor radioresistance [170]. Several
ncRNAs have been shown to play a role in cell cycle regulation after IR (Figure 4).
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5.1. miRNAs
Several miRNAs affect cell cycle arrest and as such play a role in radiosensitivity. Cyclin D1
was identified as a target gene of let-7 and miR-16. Overexpression of let-7b resulted in cyclin D1
downregulation and sensitization of uveal melanoma cells to irradiation by increasing G1 arrest
in vitro and in vivo [16]. Overexpression of miR-16 induced G0/G1 phase arrest and suppressed cell
proliferation after IR resulting in enhanced radiosensitivity of prostate cancer cells [18]. MiR-375
abrogates the cell cycle G1 arrest through inactivation of the p53 pathway in gastric cancer cells [94].
Additionally, miR-300 desensitized lung cancer cells to IR by suppressing p53-dependent G2 cell cycle
arrest [92]. Overexpression of miR-145 increased radiosensitivity of cervical cancer cells and induced
G2/M phase block [125]. CDK inhibitor p21 and anti-proliferation protein PTEN were both directly
targeted by miR-106b in colorectal cancer cells. Overexpression of miR-106b induced radioresistance in
CRC cells by promoting G1 to S transition, which was abrogated by overexpression of either PTEN
or p21 [79]. Similar to miR-106b, miR-17-mediated PTEN inhibition promoted G2 to M progression
and enhanced proliferation of NPC cells. The effect of miR-17 overexpression was mediated by AKT
signaling, as shown by reversion upon treatment with an AKT inhibitor [79]. Inhibition of c-MYC by
miR-449a resulted in IR-induced G2/M arrest in prostate cancer cells. This effect was mediated by
abrogated control of Cdc2/Cyclin B1 signaling. Additionally, both overexpression of miR-449a and
knockdown of c-MYC sensitized prostate cancer cells to IR and miR-449a also enhanced radiosensitivity
in xenograft models [66].
5.2. lncRNAs
HOTAIR was shown to regulate several aspects of cellular response to IR, amongst them cell
cycle. In cervical cancer knockdown of HOTAIR induced G1 phase arrest and thereby increased
radiosensitivity in vitro and in vivo. G1 arrest upon HOTAIR knockdown was reversed by p21
inhibition. These findings demonstrate that HOTAIR regulates cell cycle progression in response to IR
by inhibiting p21. In line with these results, HOTAIR was negatively correlated with p21 levels in
cancer tissues [113].
Cancers 2020, 12, 1662 15 of 27
Two other lncRNAs were involved in cell cycle regulation in cervical cancer: MALAT1 and NEAT1.
High levels of MALAT1 characterized radioresistant cases of cervical cancer, and IR induced MALAT1
expression in cervical cancer cell lines. Knockdown of MALAT1 enhanced radiosensitivity by inducing
apoptosis and G2/M arrest [126]. NEAT1 was also more abundant in radioresistant cases of cervical
cancer. Similarly to MALAT1, knockdown of NEAT1 enhanced radiosensitivity by inducing apoptosis
and cell cycle arrest in G1 phase. Silencing of Cyclin D1 copied the effect of NEAT1 inhibition on
radioresistance, cell cycle and apoptosis. On the other hand, Cyclin D1 overexpression or inhibition of
miR-193b, which targets Cyclin D1, partially rescued the phenotype of NEAT1 inhibition. This showed
that the effect of NEAT1 in response to IR is at least in part dependent on miR-193b and Cyclin D1.
However, in vivo experiments demonstrated that although knockdown of NEAT1 reduced tumor
volume and weight, combination with IR did not result in further reduction, and the observed effect
was even worse than radiotherapy alone. This discrepancy between in vitro and in vivo models
requires further clarification [127].
lncRNA UCA1 promoted radioresistance in colorectal and prostate cancer. UCA1 inhibition
rendered prostate cancer cells more sensitive to IR and resulted in accumulation of cells in the G2/M
phase. Mechanistically, UCA1 promoted phosphorylation of several kinases implicated in tumor
radioresistance and cell cycle regulation: AKT, FAK, FGR, and AMPKα1 [136]. Unlike in prostate
cancer, UCA1 inhibition in CRC cells attenuated the G2/M arrest induced by IR, while it promoted
apoptosis and inhibited migration and EMT of CRC cells [171]. Thus, the mechanism underlying UCA1
effect on radioresistance involves cell cycle regulation in prostate cancer, but apparently not in CRC.
6. ncRNAs Modulating Glycolysis in IR-Response
Cancer cells exhibit increased energy demand to sustain their rapid proliferation and growth.
The energy mostly derives from glycolysis, a process in which glucose is converted to pyruvate,
providing energy and intermediates for other metabolic pathways. This preference of cancer cells
for anaerobic glycolysis over oxidative phosphorylation is recognized as the Warburg effect [172].
Several glycolytic enzymes, e.g., HK2, LDHA, GLUT1, and PKM2 are upregulated in cancer cells [173].
Reprogramming of glucose metabolism in cancer cells is driven by HIF-1α and c-Myc [174]. Glycolysis
has a major contribution to radioresistance of cancer cells, and targeting glycolytic enzymes has been
shown to improve radiotherapy efficacy [175]. A number of ncRNAs are involved in determining
radiosensitivity of cancer cells by regulating glycolysis (Figure 5).
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6.1. miRNAs
Two miRNAs, miR-33a and miR-448, directly targeted HIF-1α to inhibit glycolysis and promote
radiosensitivity of cancer cells. Overexpression of miR-33a enhanced radiosensitivity of melanoma
cells in vitro and in vivo by inhibiting enzymes crucial for glycolysis: HIF-1α, HK1, HK2, and LDHA.
Overexpression of HIF-1α, a previously identified miR-33a target [176], rescued the miR-33a-mediated
inhibition of glycolysis [27]. A similar mechanism was reported for miR-448 in glioma cells. miR-448
directly targeted HIF-1α, which led to inhibition of proteins involved in glycolysis: HK1, HK2,
LDHA [64].
miR-133b sensitized NSCLC cells to IR and negatively regulated glycolysis. This effect was
mediated by targeting PKM2, an enzyme converting P-enolpyruvate to pyruvate. Overexpression of
PKM2 rescued the effect of miR-133b on radiosensitivity and glycolysis [43]. Another miRNA that
inhibited glycolysis, miR-449a, was shown to target LDHA, an enzyme which catalyzes the last step
in glycolysis, conversion of pyruvate to lactate. miR-449a mimics promoted radiosensitivity of lung
cancer cells, resulting in enhanced apoptosis and DNA damage, and reduced glycolysis rate. Silencing
of LDHA copied the effect of miR-449 overexpression on cellular response to IR [65].
6.2. lncRNAs
In addition, a lncRNA and a circRNA have been implicated in regulating glycolysis in response to
IR. Knockdown of lncRNA UCA1 enhanced radiosensitivity and reduced glycolysis rates in cervical
cancer cell lines by decreasing levels of HK2, a key enzyme involved in the first step of glycolysis.
Treatment with inhibitor of glycolysis reversed the positive effect of UCA1 overexpression on HK2
levels and radioresistance [137]. Silencing of circPITX1 promoted radiosensitivity of glioma cells
in vitro and in vivo by inhibiting glycolysis. circPITX1 acted as a sponge for miR-329-3p to protect
NEK2 from miRNA-mediated inhibition. The relevance of the circPITX1/miR-329-3p/NEK2 axis in
radioresistance and glycolysis was confirmed by rescue experiments and inhibition of glycolysis [107].
Although not directly involved in glycolysis, NEK2 was previously shown to regulate splicing of
pyruvate kinase M2 (PKM2), a key player in this pathway [177].
7. ncRNAs Affecting the Wnt/β-Catenin Pathway in Response to IR
The Wnt/β-catenin signaling is an example of an oncogenic pro-survival pathway hyperactivated
in many types of cancer [178,179] and promotes reprogramming of cancer cell metabolism and
cancer immunity [180]. Recently, the Wnt/β-catenin pathway has also been implicated in stimulating
radioresistance of cancer cells by affecting cell cycle, apoptosis, DNA repair, and cell proliferation [181].
Several miRNAs and lncRNAs have also been implicated in the Wnt/β-catenin pathway (Figure 6).
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7.1. miRNAs
miR-320 directly targeted β-catenin in cervical cancer cells. Both overexpression of miR-320 and
knockdown of β-catenin promoted radiosensitivity of cervical cancer cells. In line with this, miRNA-320
levels were decreased and β-catenin levels increased in radioresistant cervical cancer cells compared to
more sensitive parental cells [61].
Contradictory effects of miR-301a on Wnt/β-catenin signaling pathway and radiosensitivity
were demonstrated. miR-301a was shown to directly target Wnt that activates and TCEAL7 that
suppress β-catenin signaling [58,93]. Upregulation of miR-301a directly inhibited Wnt and indirectly
β-catenin and cyclin D1 in ESCC cells and this led to increased radiosensitivity, reduced proliferation
and migration of ESCC cells [58]. In contrast, miR-301a-mediated TCEAL7 inhibition increased
transcriptional activity of β-catenin. Moreover, inhibition of miR-301a and overexpression of TCEAL7
reversed the radioresistant miR-301a phenotype in GMB cells in vitro and in vivo [93]. These opposite
effects could be attributed to a cell-line specific miR-301a function.
miR-185-3p sensitized NPC cells to IR by targeting Wnt2B protein and an inverse relationship
between expression levels of miR-185-3p and Wnt2B was confirmed in NPC cells and tissues [50]. Wnt2B
is also targeted by miR-324-3p, whose overexpression increased radiosensitivity and impaired Wnt2B
signaling after IR. Furthermore, miR-324-3p levels decreased and Wnt2B levels increased in NPC tissues
after radiotherapy [62]. In addition, miR-1275 directly targeted Wnt1 in ESCC cells. Overexpression of
miR-1275 enhanced radiosensitivity via inhibition of the epithelial to mesenchymal transition (EMT).
Moreover, miR-1275 reduced tumor growth and promoted radiosensitivity in vivo [71].
7.2. lncRNAs
A handful of lncRNAs have been linked to IR response by regulating the Wnt/β-catenin pathway.
lincRNA-p21 was downregulated in gastric cancer and CRC cells and tissues [99,100]. Ectopic
overexpression of lincRNA-p21 enhanced radiosensitivity and inhibited the Wnt/β-catenin pathway
in both tumor types. Levels of β-catenin and its target genes, c-MYC and Cyclin D1, were also
downregulated upon lincRNA-p21 overexpression, as well as upon IR in CRC [100]. Inhibition of
the β-catenin pathway abolished the effects of lincRNA-p21 overexpression on cell proliferation and
radiosensitivity in gastric cancer cells [99]. This supports the role of lincRNA-p21 in promoting
radiosensitivity by inhibiting the Wnt/β-catenin pathway.
In pancreatic ductal adenocarcinoma (PDAC) cells HOTAIR was induced by IR, while its
knockdown enhanced radiosensitivity. Upon HOTAIR knockdown expression of Wnt inhibitory factor
1 (WIF-1) was increased and in line with that, levels of HOTAIR and WIF-1 were negatively correlated
in clinical samples. Furthermore, overexpression of WIF-1 enhanced radiosensitivity of PDAC cells,
copying the effect of HOTAIR knockdown [114]. Although the activity of Wnt/β-catenin pathway was
not assessed in these experiments, the authors suggest that HOTAIR may be involved in IR response in
PDAC cells by promoting this pathway.
WISP1 is a downstream target of Wnt/β-catenin pathway. It was upregulated in ESCC tissues
and promoted radioresistance of ESCC cells in vitro and in vivo. Knockdown of lncRNA BOKAS,
an IR-induced lncRNA, reduced expression of WISP1 upon IR [104]. However, it was not demonstrated
whether BOKAS affects WISP1 via the Wnt/β-catenin pathway or if some other mechanism is involved.
8. Conclusions
Non-coding RNAs have emerged as key regulators in various processes in health and disease.
In cancer, ncRNAs have been shown to contribute to carcinogenesis, differentiate between cancer
subtypes, predict prognosis, and influence treatment outcome. Radiation is a treatment of choice for
many cancer types. However, while some tumors are sensitive to radiotherapy, others demonstrate
radioresistance. Therefore, mechanisms underlying tumor radioresistance and potential options of
combination therapy to improve the outcome are being investigated. Here, we have summarized
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the current knowledge on the role of ncRNAs in determining the radiosensitivity of various cancers.
From this review, it is evident that miRNAs and lncRNAs are involved in many aspects of cellular
response to radiation. While some promote tumor radiosensitivity, others render tumors more
radioresistant. Expression levels of several of these ncRNAs are also affected by IR. One of the
key players in IR response, p53, regulates the expression of several miRNAs (e.g., miR-34 [182])
and lncRNAs (e.g., Damage Induced Noncoding RNA (DINO) [183]), and can itself be regulated
by ncRNAs [182,184]. Many ncRNAs have been associated with response to radiotherapy and can
be used to predict efficacy of radiation treatment. Functional studies revealed different underlying
mechanisms, involving crucial aspects of cellular response to IR, such as DNA damage repair, cell cycle
control, apoptosis etc. Moreover, in vitro and in vivo studies demonstrated that modulation of the
levels of ncRNAs can significantly enhance radiosensitivity of tumor cells. This indicates that ncRNAs
may be used as targets to improve outcome of radiotherapy. The functional relevance was shown for
multiple ncRNAs, indicating a great potential in combination radiotherapy. In recent years, several
preclinical and clinical trials targeting ncRNAs, especially miRNAs, have been initiated. This further
demonstrates the therapeutic potential of targeting RNA. With the development of advanced delivery
strategies for RNA-based therapeutics, new combined radio-RNA therapies can emerge. Next to this,
more studies are needed to identify ncRNAs serving as biomarkers of response to radiation in different
cancer types. Further functional studies to determine underlying mechanisms of ncRNAs promoting
radiosensitivity or radioresistance, as well as confirmation using in vivo models are also warranted.
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